利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5248 条记录 (耗时 0.064 秒)

    Target-Specific Non-Antibody Protein and Method for Preparing the Same
    81.
    发明申请
    Target-Specific Non-Antibody Protein and Method for Preparing the Same 有权
    靶向特异性非抗体蛋白及其制备方法

    公开(公告)号：US20120071419A1

    公开(公告)日：2012-03-22

    申请号：US13264365

    申请日：2010-04-14

    申请人： Yoon Sup Choi ,  Jun Ho Chung ,  Ji Ho Yoo ,  Hyun Soo Cho ,  Su Min Yoon ,  Kyung Lock Kim ,  Sung Ho Ryu ,  Sang Uk Kim

    发明人： Yoon Sup Choi ,  Jun Ho Chung ,  Ji Ho Yoo ,  Hyun Soo Cho ,  Su Min Yoon ,  Kyung Lock Kim ,  Sung Ho Ryu ,  Sang Uk Kim

    IPC分类号： A61K38/02 ,  C07K1/00 ,  C12N15/12 ,  C12N15/63 ,  C07K14/47 ,  A61P35/00 ,  C12N1/19 ,  C12N1/15 ,  C12N1/21 ,  C07K14/00 ,  C12N5/10

    CPC分类号： C07K14/485 ,  A61K38/00 ,  C07K1/00 ,  C12N15/1089 ,  C40B30/02 ,  G06F19/16 ,  G06F19/18 ,  G06F19/22

    摘要： The present invention relates to a method for preparing a target-specific non-antibody protein, and more particularly, to a method for preparing a target-specific non-antibody protein comprising the steps of: selecting non-antibody proteins having a structural complementarity with the target site of a target protein in a non-antibody protein library; calculating a binding energy of the selected non-antibody protein and the target protein; selecting a non-antibody protein having a favorable binding energy among the selected non-antibody proteins; selecting amino acid residues having a high binding energy among the interfacial amino acid residues of the selected non-antibody protein and the target protein; and substituting the selected amino acid residues with the amino acid residues having a low binding energy. In addition, the present invention relates to a target-specific non-antibody specifically binding with EGFR (Epidermal Growth Factor Receptor) domain 2, which is prepared by the method, and a cancer therapeutic composition comprising the same.

    摘要翻译： 本发明涉及一种制备靶特异性非抗体蛋白质的方法，更具体地涉及一种制备靶特异性非抗体蛋白质的方法，包括以下步骤：选择具有结构互补性的非抗体蛋白质 非抗体蛋白文库中靶蛋白的靶位点; 计算所选择的非抗体蛋白质和靶蛋白质的结合能; 选择所选非抗体蛋白质中具有良好结合能的非抗体蛋白质; 选择所选非抗体蛋白质的界面氨基酸残基与目标蛋白质之间具有高结合能的氨基酸残基; 并用具有低结合能的氨基酸残基代替所选择的氨基酸残基。 此外，本发明涉及通过该方法制备的与EGFR（表皮生长因子受体）结构域2特异性结合的靶特异性非抗体，以及含有该特异性抗体的癌症治疗组合物。

    Selectively replicating viral vectors
    83.
    发明授权
    Selectively replicating viral vectors 有权
    选择性复制病毒载体

    公开(公告)号：US08133481B2

    公开(公告)日：2012-03-13

    申请号：US12706134

    申请日：2010-02-16

    申请人： Muralidhara Ramachandra ,  Paul W. Shabram

    发明人： Muralidhara Ramachandra ,  Paul W. Shabram

    IPC分类号： A01N63/00 ,  A61K35/713 ,  A61K48/00 ,  C07H21/04 ,  C12N15/00 ,  C12N15/12 ,  C12N15/34

    CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2830/00 ,  C12N2830/001 ,  C12N2830/15

    摘要： The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.

    摘要翻译： 本发明提供了通过使用基于感染细胞的表型或基因型基本上抑制宿主细胞中的病毒复制的途径反应性启动子来响应于靶细胞的细胞内条件而选择性复制病毒基因的重组病毒。 在靶细胞中，途径反应性启动子的启动子元件是无活性的，因此病毒被允许复制。 这导致：（1）通过病毒的天然裂解性质杀死细胞，和/或（2）向靶细胞提供治疗剂量的转基因产物（与复制无能载体相比扩增），和（3） 产生该病毒的局部浓度，促进周围细胞感染重组病毒。 本发明还提供了使用载体的治疗和诊断方法，包含载体的药物制剂，制备载体的方法和包含载体的转化细胞。

    Method of predicting metastasis of oral cavity cancer into cervical lymph node and diagnosis kit to be used in the prediction
    85.
    发明授权
    Method of predicting metastasis of oral cavity cancer into cervical lymph node and diagnosis kit to be used in the prediction 失效
    预测口腔癌转移到宫颈淋巴结的方法和预测中使用的诊断试剂盒

    公开(公告)号：US08129122B2

    公开(公告)日：2012-03-06

    申请号：US12310331

    申请日：2007-03-30

    申请人： Takashi Imai ,  Mayumi Iwakawa ,  Hitoshi Shibuya ,  Masahiko Miura ,  Ryoichi Yoshimura ,  Hiroshi Watanabe

    发明人： Takashi Imai ,  Mayumi Iwakawa ,  Hitoshi Shibuya ,  Masahiko Miura ,  Ryoichi Yoshimura ,  Hiroshi Watanabe

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12N15/11 ,  C12N15/12

    CPC分类号： G01N33/57407 ,  C12Q1/6886 ,  C12Q2600/118 ,  G01N2333/705 ,  G01N2333/71

    摘要： A method for objectively predicting possibility of metastasis to a cervical lymph node in an early stage for an individual case diagnosed as an oral cavity cancer, and a diagnosis kit to be used in the prediction are provided. The method includes a step of assaying expression amounts of metastasis prediction genes in which the expression amounts are changed between a metastasis group and a non-metastasis group, with respect to a sample collected from a primary legion of the oral cavity cancer. Further, the method includes a step of predicting the possibility of the metastasis by comparing the expression amounts of the metastasis gene group with the expression amounts of the metastasis prediction genes in a metastasis group and/or a non-metastasis group. Herein, the metastasis prediction gene group includes two genes MSR1 (NM_138716.1) and RET (M31213.1).

    摘要翻译： 提供了用于客观预测诊断为口腔癌的个别病例的早期颈部淋巴结转移可能性的方法，以及用于预测的诊断试剂盒。 该方法包括相对于从口腔癌的主要团队收集的样品，测定转移组和非转移组之间的表达量发生变化的转移预测基因的表达量的步骤。 此外，该方法包括通过将转移基因组的表达量与转移组和/或非转移组中的转移预测基因的表达量进行比较来预测转移的可能性的步骤。 这里，转移预测基因组包括两个基因MSR1（NM_138716.1）和RET（M31213.1）。

    METHODS AND COMPOSITIONS FOR INHIBITING PROPAGATION OF VIRUSES USING RECOMBINANT TETHERIN CONSTRUCTS
    88.
    发明申请
    METHODS AND COMPOSITIONS FOR INHIBITING PROPAGATION OF VIRUSES USING RECOMBINANT TETHERIN CONSTRUCTS 审中-公开
    用重组蛋白构建体抑制病毒传播的方法和组合物

    公开(公告)号：US20120039858A1

    公开(公告)日：2012-02-16

    申请号：US13124559

    申请日：2009-10-16

    申请人： Paula Cannon

    发明人： Paula Cannon

    IPC分类号： A61K48/00 ,  C07H21/00 ,  A61P31/12 ,  C12N1/00 ,  C12N5/10 ,  A61P31/18 ,  C07K19/00 ,  C12N15/12

    CPC分类号： C07K14/705 ,  A61K48/00 ,  C07K2319/03 ,  C12N2830/008 ,  C12N2830/60

    摘要： The present invention provides chimeric protein constructs having anti-viral activity, compositions and methods of using them, and nucleic acids encoding them. The chimeric proteins include an extracellular domain of a Tetherin protein fused to the transmembrane domain, and optionally cytoplasmic tail, of a different protein. The chimeric proteins have normal anti-viral tethering activity but are resistant to inhibition by anti-Tetherins. Ex vivo methods of gene therapy are also provided.

    摘要翻译： 本发明提供了具有抗病毒活性的嵌合蛋白构建体，使用它们的组合物和方法以及编码它们的核酸。 嵌合蛋白包括与跨膜结构域和任选的细胞质尾部融合的不同蛋白质的Tether蛋白的细胞外结构域。 嵌合蛋白具有正常的抗病毒束缚活性，但抗抗栓剂的抑制作用。 还提供了基因治疗的离体方法。

    Retinal dystrophy-associated protein and uses thereof
    89.
    发明授权
    Retinal dystrophy-associated protein and uses thereof 有权
    视网膜营养不良相关蛋白及其用途

    公开(公告)号：US08114849B2

    公开(公告)日：2012-02-14

    申请号：US11739739

    申请日：2007-04-25

    申请人： Thierry Leveillard ,  Jose Alain Sahel ,  Saddek Mohand-Said ,  David Hicks

    发明人： Thierry Leveillard ,  Jose Alain Sahel ,  Saddek Mohand-Said ,  David Hicks

    IPC分类号： C12N15/11 ,  C12N15/12 ,  C12N15/861

    CPC分类号： A61K38/1709 ,  C07K14/47

    摘要： Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.

    摘要翻译： 公开了用于早期诊断，监测和治疗视网膜营养不良，年龄相关性黄斑变性，Bardet-Biedel综合征，Bassen-kornzweig综合征，最佳疾病，脉络膜炎，旋转萎缩，先天性青春期，refsun综合征，星状病和Usher的方法和组合物 综合征 特别地，本发明涉及一种被称为“Rdcvf1”的蛋白质，其在非视网膜营养不良症等视网膜营养不良症和与年龄相关的黄斑变性患者中差异转录并表达，与非患者相比，识别的抗体 这种蛋白质，以及用于诊断这些病症的方法。